Does the media favor VTGN or CNTX?

In the previous week, VistaGen Therapeutics and VistaGen Therapeutics both had 2 articles in the media. VistaGen Therapeutics' average media sentiment score of 0.93 equaled Context Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALGS or VTGN?

In the previous week, Aligos Therapeutics and Aligos Therapeutics both had 2 articles in the media. Aligos Therapeutics' average media sentiment score of 0.93 equaled VistaGen Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VTGN or EDSA?

In the previous week, VistaGen Therapeutics and VistaGen Therapeutics both had 2 articles in the media. Edesa Biotech's average media sentiment score of 0.94 beat VistaGen Therapeutics' score of 0.93 indicating that Edesa Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edesa Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GOSS or VTGN?

In the previous week, Gossamer Bio had 11 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 13 mentions for Gossamer Bio and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.93 beat Gossamer Bio's score of 0.31 indicating that VistaGen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

VistaGen Therapeutics (VTGN) Competitors

$0.25 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$0.25 0.00 (-0.36%)

As of 08:17 AM Eastern

Compare

VTGN vs. CNTX, ALGS, EDSA, GOSS, and MDXH

Should you buy VistaGen Therapeutics stock or one of its competitors? VistaGen Therapeutics's main competitors and comparable companies include Context Therapeutics (CNTX), Aligos Therapeutics (ALGS), Edesa Biotech (EDSA), Gossamer Bio (GOSS), and MDxHealth (MDXH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does VistaGen Therapeutics compare to Context Therapeutics?

VistaGen Therapeutics (NASDAQ:VTGN) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

VistaGen Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market.

Context Therapeutics has lower revenue, but higher earnings than VistaGen Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	8.84	-$69.68M	-$1.66	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

Context Therapeutics has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. Context Therapeutics' return on equity of -82.06% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%
Context Therapeutics	N/A	-82.06%	-72.74%

VistaGen Therapeutics currently has a consensus price target of $0.95, suggesting a potential upside of 275.64%. Context Therapeutics has a consensus price target of $6.17, suggesting a potential upside of 1,507.16%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, VistaGen Therapeutics and VistaGen Therapeutics both had 2 articles in the media. VistaGen Therapeutics' average media sentiment score of 0.93 equaled Context Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Context Therapeutics beats VistaGen Therapeutics on 10 of the 13 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Aligos Therapeutics currently has a consensus target price of $38.50, indicating a potential upside of 457.16%. VistaGen Therapeutics has a consensus target price of $0.95, indicating a potential upside of 275.64%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Aligos Therapeutics has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

Aligos Therapeutics has higher revenue and earnings than VistaGen Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	19.69	-$24.19M	-$7.30	N/A
VistaGen Therapeutics	$1.27M	8.84	-$69.68M	-$1.66	N/A

Aligos Therapeutics has a net margin of -241.01% compared to VistaGen Therapeutics' net margin of -2,702.64%. VistaGen Therapeutics' return on equity of -152.59% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%

In the previous week, Aligos Therapeutics and Aligos Therapeutics both had 2 articles in the media. Aligos Therapeutics' average media sentiment score of 0.93 equaled VistaGen Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Aligos Therapeutics beats VistaGen Therapeutics on 11 of the 15 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Edesa Biotech?

VistaGen Therapeutics (NASDAQ:VTGN) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Edesa Biotech has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. VistaGen Therapeutics' return on equity of -152.59% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%
Edesa Biotech	N/A	-560.22%	-105.74%

In the previous week, VistaGen Therapeutics and VistaGen Therapeutics both had 2 articles in the media. Edesa Biotech's average media sentiment score of 0.94 beat VistaGen Therapeutics' score of 0.93 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edesa Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

VistaGen Therapeutics has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

VistaGen Therapeutics currently has a consensus target price of $0.95, indicating a potential upside of 275.64%. Edesa Biotech has a consensus target price of $5.00, indicating a potential upside of 8.23%. Given VistaGen Therapeutics' higher probable upside, research analysts plainly believe VistaGen Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Edesa Biotech has lower revenue, but higher earnings than VistaGen Therapeutics. Edesa Biotech is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	8.84	-$69.68M	-$1.66	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Edesa Biotech beats VistaGen Therapeutics on 9 of the 15 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Gossamer Bio has a net margin of -235.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. Gossamer Bio's return on equity of 0.00% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%

VistaGen Therapeutics has lower revenue, but higher earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.82	-$170.37M	-$0.70	N/A
VistaGen Therapeutics	$1.27M	8.84	-$69.68M	-$1.66	N/A

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 3.7% of Gossamer Bio shares are owned by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Gossamer Bio presently has a consensus price target of $3.20, suggesting a potential upside of 1,781.25%. VistaGen Therapeutics has a consensus price target of $0.95, suggesting a potential upside of 275.64%. Given Gossamer Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Gossamer Bio is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Gossamer Bio has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

In the previous week, Gossamer Bio had 11 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 13 mentions for Gossamer Bio and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.93 beat Gossamer Bio's score of 0.31 indicating that VistaGen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Gossamer Bio beats VistaGen Therapeutics on 12 of the 16 factors compared between the two stocks.

How does VistaGen Therapeutics compare to MDxHealth?

VistaGen Therapeutics (NASDAQ:VTGN) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

MDxHealth has a net margin of -33.46% compared to VistaGen Therapeutics' net margin of -2,702.64%. MDxHealth's return on equity of 0.00% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%
MDxHealth	-33.46%	N/A	-24.25%

78.4% of VistaGen Therapeutics shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by company insiders. Comparatively, 1.7% of MDxHealth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

VistaGen Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

VistaGen Therapeutics presently has a consensus target price of $0.95, indicating a potential upside of 275.64%. MDxHealth has a consensus target price of $2.17, indicating a potential upside of 200.63%. Given VistaGen Therapeutics' higher possible upside, equities research analysts clearly believe VistaGen Therapeutics is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

MDxHealth has higher revenue and earnings than VistaGen Therapeutics. MDxHealth is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	8.84	-$69.68M	-$1.66	N/A
MDxHealth	$114.02M	0.31	-$33.52M	-$0.72	N/A

In the previous week, VistaGen Therapeutics had 1 more articles in the media than MDxHealth. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 1 mentions for MDxHealth. VistaGen Therapeutics' average media sentiment score of 0.93 beat MDxHealth's score of 0.54 indicating that VistaGen Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
VistaGen Therapeutics	Positive
MDxHealth	Positive

Summary

MDxHealth beats VistaGen Therapeutics on 9 of the 16 factors compared between the two stocks.

Get VistaGen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTGN vs. The Competition

Export

Metric	VistaGen Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.22M	$3.94B	$7.18B	$12.88B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-0.15	11.68	273.17	25.45
Price / Sales	8.84	1,405.93	637.96	103.56
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	0.28	16.92	11.08	6.36
Net Income	-$69.68M	-$22.74M	$3.48B	$349.79M
7 Day Performance	3.73%	-0.13%	0.21%	-0.48%
1 Month Performance	4.94%	11.45%	7.75%	4.17%
1 Year Performance	-92.43%	55.66%	24.68%	15.11%

VistaGen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTGN VistaGen Therapeutics	2.4481 of 5 stars	$0.25 flat	$0.95 +275.6%	-92.4%	$11.22M	$1.27M	N/A	40
CNTX Context Therapeutics	2.8349 of 5 stars	$0.47 +1.0%	$6.17 +1,212.1%	-54.3%	$43.18M	N/A	N/A	7	News Coverage Gap Up
ALGS Aligos Therapeutics	3.6842 of 5 stars	$6.92 -0.2%	$38.50 +456.8%	-34.5%	$42.95M	$2.19M	N/A	90
EDSA Edesa Biotech	1.4313 of 5 stars	$4.53 +3.0%	$5.00 +10.4%	+95.8%	$42.62M	N/A	N/A	20
GOSS Gossamer Bio	2.7722 of 5 stars	$0.18 +0.6%	$3.20 +1,718.2%	-93.1%	$40.60M	$48.47M	N/A	180	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTGN) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. CNTX, ALGS, EDSA, GOSS, and MDXH

How does VistaGen Therapeutics compare to Context Therapeutics?

Summary

How does VistaGen Therapeutics compare to Aligos Therapeutics?

Summary

How does VistaGen Therapeutics compare to Edesa Biotech?

Summary

How does VistaGen Therapeutics compare to Gossamer Bio?

Summary

How does VistaGen Therapeutics compare to MDxHealth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. CNTX, ALGS, EDSA, GOSS, and MDXH

How does VistaGen Therapeutics compare to Context Therapeutics?

Which has more risk and volatility, VTGN or CNTX?

Which has higher earnings and valuation, VTGN or CNTX?

Is VTGN or CNTX more profitable?

Do analysts rate VTGN or CNTX?

Does the media favor VTGN or CNTX?

Do institutionals and insiders hold more shares of VTGN or CNTX?

Summary

How does VistaGen Therapeutics compare to Aligos Therapeutics?

Do analysts rate ALGS or VTGN?

Which has more volatility & risk, ALGS or VTGN?

Which has stronger valuation and earnings, ALGS or VTGN?

Is ALGS or VTGN more profitable?

Does the media refer more to ALGS or VTGN?

Do institutionals and insiders have more ownership in ALGS or VTGN?

Summary

How does VistaGen Therapeutics compare to Edesa Biotech?

Is VTGN or EDSA more profitable?

Does the media prefer VTGN or EDSA?

Which has more risk and volatility, VTGN or EDSA?

Do analysts prefer VTGN or EDSA?

Which has stronger earnings and valuation, VTGN or EDSA?

Do institutionals and insiders believe in VTGN or EDSA?

Summary

How does VistaGen Therapeutics compare to Gossamer Bio?

Is GOSS or VTGN more profitable?

Which has stronger earnings and valuation, GOSS or VTGN?

Do institutionals & insiders hold more shares of GOSS or VTGN?

Do analysts prefer GOSS or VTGN?

Which has more volatility & risk, GOSS or VTGN?

Does the media refer more to GOSS or VTGN?

Summary

How does VistaGen Therapeutics compare to MDxHealth?

Is VTGN or MDXH more profitable?

Do institutionals and insiders have more ownership in VTGN or MDXH?

Which has more risk and volatility, VTGN or MDXH?

Do analysts rate VTGN or MDXH?

Which has preferable earnings & valuation, VTGN or MDXH?

Does the media prefer VTGN or MDXH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools